Evolus to Participate in Two Upcoming Investor Conferences
November 01 2018 - 8:01AM
Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic
medicine, announced today that members of management will be
participating in two upcoming investor conferences.
Event: |
Stifel 2018 Healthcare
Conference |
Format: |
Presentation & 1x1
Meetings |
Date: |
Tuesday, November 13,
2018 |
Time: |
8:00 a.m. ET
presentation |
Location: |
New York, NY |
|
|
Event: |
Jefferies 2018 London
Healthcare Conference |
Format: |
1x1 Meetings |
Date: |
Wednesday November 14
& Thursday, November 15, 2018 |
Location: |
London, UK |
An audio webcast of the Company’s presentation at the Stifel
2018 Healthcare Conference will be available on the investor
relations section of Evolus’ website at investors.evolus.com. A
replay of the webcast will be available for 90 days after the date
of the presentation.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on
providing physicians and their patients with expanded choices in
aesthetic treatments and procedures. Evolus’ lead candidate
DWP-450, also known by the chemical name prabotulinumtoxinA, is a
900 kDa purified botulinum toxin type A complex that was approved
by Health Canada for the temporary improvement in the appearance of
moderate to severe glabellar lines in adult patients under 65 years
of age and is being evaluated for marketing approval in the United
States and other areas.
Evolus Contacts:
Investors Ashwin Agarwal, Evolus Tel:
+1-949-284-4559
Email: IR@Evolus.com
Brian Johnston, The Ruth Group Tel: +1 646-536-7028
Email: IR@Evolus.com
General Media Kirsten Thomas, The Ruth
Group Tel: +1-508-280-6592 Email: kthomas@theruthgroup.com
Trade Media Dani Shaffer, Alison Brod
Marketing + Communications Tel: +1-212-230-1800
Email: evolus@alisonbrodmc.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024